fingolimod
UkraineDrugs containing this active substance
-
The drug is prescribed for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis. This applies to patients who have not responded to previous treatment or those experiencing frequent exacerbations or new lesions on MRI.
Form: capsules, hard
Active substance Dosage fingolimod 0.5 mg ATC: L04AE01
Manufacturer: Farmaten International S.A. (manufacturing, primary and secondary packaging, batch control)
-
The drug is intended for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis or with a rapidly progressive, severe course of the disease.
Form: capsules, hard
Active substance Dosage fingolimod 0.5 mg ATC: L04AA27
-
The drug is indicated for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis.
Form: capsules
Active substance Dosage fingolimod 0.5 mg ATC: L04AA27
Manufacturer: Synthon Chile Ltda. (manufacturing, primary, secondary packaging, quality control)
-
The drug is intended for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis. This applies to patients for whom previous treatment has been ineffective, or those experiencing frequent exacerbations or new lesions on MRI.
Form: capsules
Active substance Dosage fingolimod 0.5 mg ATC: L04AA27
Manufacturer: Hetero Labs Limited
-
It is used for the treatment of adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis, particularly in cases where previous treatment has been ineffective or in cases of rapidly progressing severe disease.
Form: capsules, hard
Active substance Dosage fingolimod 0.5 mg ATC: L04AA27
Manufacturer: Dr. Reddy's Laboratories Ltd, FTO-7
-
The drug is indicated for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis. This applies to patients who have not responded to a previous course of treatment or those experiencing a rapidly progressive, severe course of the disease.
Form: capsules, hard
Active substance Dosage fingolimod 0.5 mg ATC: L04AA27
Manufacturer: Novartis Pharma Stein AG (manufacturing, quality control, packaging, batch release)